Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CheckMate 142 Updated Analysis - The ASCO Post
CheckMate 142 ：纳武利尤单抗+低剂量伊匹木单抗一线治疗 MSI-H/dMMR 转移性结直肠癌的疗效和安全性_患者
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 ...
CheckMate 8HW: Nivolumab + Ipilimumab Improves PFS in dMMR/MSI-H CRC
CheckMate 8HW: Nivolumab + Ipilimumab Improves PFS in dMMR/MSI-H CRC ...
CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option ...
Results from CheckMate 743: first-line nivolumab plus ipilimumab in ...
CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC - VJOncology
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus ...
CheckMate 8HW: Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic ...
CheckMate 8HW: Nivolumab + Ipilimumab Shows Durable PFS Benefit in MSI ...
Nivolumab in patients with metastatic DNA mismatch repair-deficient or ...
Nivolumab plus relatlimab in patients with previously treated ...
第2回座談会 MSI-H大腸癌に対するNivolumab＋Ipilimumab併用療法への期待 | 座談会 | OncoTribune
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite ...
Nivolumab plus low-dose ipilimumab in previously treated patients with ...
大腸癌 CheckMate-142（Nivolumab） | 臨床試験サマリ | OncoTribune
STUDIU: Imunoterapia cu nivolumab+ipilimumab, eficientă pentru cancerul ...
Nivolumab聯合ipilimumab用於dMMR/MSI-H 的轉移性結直腸癌 - 每日頭條
Nivolumab plus ipilimumab and cobimetinib in previously treated ...
ASCO GU 2020: Overall Survival and Independent Review of Response in ...
dMMR/MSI-Hの切除不能進行・再発大腸癌に対するNivolumab＋Ipilimumab併用療法のupdate解析（CheckMate ...
(PDF) Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and ...
Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of ...
Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab ...
MSI大腸癌に対するイピニボのCheckMate142試験 - レ点腫瘍学ノート
Emerging Considerations in the Use of Immune Checkpoint Inhibitors ...
Table 1 from First-Line Nivolumab Plus Low-Dose Ipilimumab for ...
ASCO 2025: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
Nivolumab plus low-dose ipilimumab as a first-line treatment for MSI-H ...
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of ...
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch ...
Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in ...
Table 1 from Nivolumab in patients with metastatic DNA mismatch repair ...
J Clin Oncol：纳武单抗联合低剂量伊匹单抗一线治疗MSI-H/dMMR转移性结直肠癌的疗效-MedSci.cn
(PDF) Safety and efficacy of nivolumab plus ipilimumab in patients with ...
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized ...
CheckMate-8HW: Nivolumab/Ipilimumab Demonstrates Improved Outcomes Over ...
Safety and efficacy of nivolumab plus ipilimumab in patients with ...
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk ...
(PDF) Nivolumab plus ipilimumab versus sunitinib for first-line ...
Ipilimumab and Nivolumab for dMMR/MSI-H Colorectal Cancer
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
CheckMate-142 Update Simultaneously Published and Presented: Results ...
IASLC WCLC 2020: CheckMate-743 shows that dual immunotherapy, nivolumab ...
IKCS 2022: Efficacy and Safety of Nivolumab plus Ipilimumab Versus ...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of ...
Nivolumab plus ipilimumab as first-line treatment for advanced non ...
2020 ASCO回顾|CheckMate 142双免疫联合一线治疗的2年随访更新数据公布，肠癌治疗再获突破医药新闻-ByDrug-一站式医药 ...
(PDF) Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of ...
Safety Profile of Nivolumab Plus Ipilimumab Combination Therapy
Nivolumab plus ipilimumab combination therapy in patients with advanced ...
SIU 2021: New Systemic Therapies in Advanced Renal Cell Carcinoma
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With ...
Concordance of DNA mismatch repair deficient (dMMR)/microsatellite ...
【2019 ASCO速递】真的有戏！双免疫联合治疗消化道肿瘤新进展
30422-9/asset/83bc8215-2ebd-48db-8bf7-b1bb101ed192/main.assets/gr1_lrg.jpg)
30422-9/asset/dde80051-e47d-49f5-8ebc-3de6662eb4bb/main.assets/gr2_lrg.jpg)
30624-6/asset/3b07a6b8-6cc9-4142-9f13-00b946a0a0d5/main.assets/gr2_lrg.jpg)
